Effects of pioglitazone on coronary atherosclerotic plaques of patients with impaired glucose tolerance or type 2 diabetes mellitus:a randomized,open rabelled,prospective study.
Phase 2
- Conditions
- Impaired glucose tolerance or type 2 diabetes mellitus with coronary artery disease
- Registration Number
- JPRN-C000000230
- Lead Sponsor
- Chiba University Graduate School of Medicine
- Brief Summary
Published: Nakayama T, Komiyama N, Yokoyama M, Namikawa S, Kuroda N, Kobayashi Y, Komuro I. Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound. Int J Cardiol. 2010;138(2):157-165. Epub 2008 Sep 24.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Heart failure,acute myocardial infarction,severe hepatic or renal dysfunction,to take insulin,already to take pioglitazone,episode of adverse effect by troglitazone,pregnancy and severe hypercholesterolemia.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plaque volume,vessel volume,lumen volume and radiofrquency data assessed with intravascular ultrasound. Plasma glucose,HbA1C,insulin,total cholesterol,triglyceride,LDL,HDL,MDA-LDL,8-isoprostane,MMP-9,MCP-1,PAI-1,TNF-a and hsCRP. Major adverse cardiovascular event and harmful effect of pioglitazone
- Secondary Outcome Measures
Name Time Method Plasma GOT,GPT,T-BIL,CPK,ALP,G-GTP and LDH